Prediction of Long-term Scalp Hair Regrowth at 24 Months in Patients with Alopecia Areata Receiving Ritlecitinib Treatment in the ALLEGRO Clinical Trial Program
Hannah Humphries, Rodney Sinclair, Bianca Maria Piraccini, Laurent Misery, C. Abasq, Julien Ringuet, Dalia Wajsbrot, Roger Edwards, Gianluca Bonfanti, Robert Wołk, Alexandre Lejeune, Brett King
We don't know much about this study yet.
We're maintaining the world's largest resposity of hair loss
research. You can help out the community by
sending a PDF of this study here
.
Not sure how to get a study's PDF? You can email the authors
of the study.
A potential treatment for alopecia involving a protein that calms hair follicles has shown promise in rats, but skepticism remains about its applicability to humans. Many users express doubt about the timeline for effective hair loss treatments, comparing it to past unfulfilled promises.
The user has tried many hair loss treatments including dutasteride, oral and topical minoxidil, topical finasteride, PRP, and microneedling without much success and is now using RU58841, seeing initial vellus hair growth but no further improvement after 5 months. They are inquiring about the effectiveness of RU58841 after 6-12 months of use.
PP405 shows promise for hairregrowth, with new hairs observed in 66% of patients in just 27 days. The discussion also mentions Minoxidil, finasteride, and RU58841 as potential treatments.
Treatments for hair loss, including topical dutasteride minoxidil, tretonin, dermarolling, serioxyl, and redensyl over a period of 3 months; switching from RU58841 to pyrilutamide was suggested with potentially less risk of systemic side effects; and encouragement to not give up hope.
The user is cautiously optimistic about their hairregrowth after 6 months of using minoxidil, finasteride, tazarotene, microneedling, ketoconazole shampoo, and rosemary oil. They report healthier hair and new growth, with side effects from minoxidil subsiding over time.
ABS-201 shows promise for male hairregrowth by blocking the prolactin receptor, with higher expected efficacy than current treatments. The discussion also covers dosing differences between macaques and humans for hmi115, highlighting a significant dosage disparity.